EDAP TMS reports 140% QoQ Focal One net placement growth, 76.8% YoY HIFU rev. growth.
PorAinvest
jueves, 28 de agosto de 2025, 7:04 am ET1 min de lectura
EDAP--
The announcement follows a strong financial performance, with Focal One net placement growing 140% year-over-year (YoY) and HIFU revenue increasing by 76.8% YoY. The company has also raised its 2025 HIFU revenue growth guidance to a range of 26% to 34%.
CEO Ryan Rhodes highlighted the strategic significance of the financing, stating, "The capital raised through this financing immediately enhances our balance sheet, offering a substantial source of low-interest funding that we can access in tranches as needed. Over the last several years, the EIB has been an extraordinary partner in helping companies deliver new and promising innovative technologies for the benefit of millions of patients across the globe. I would like to thank the EIB for their support, as we believe this additional capital will enable more physicians and their patients to access the benefits of Focal One Robotic HIFU."
EDAP TMS SA is recognized for its innovation in robotic energy-based therapies, combining ultrasound technology with advanced imaging and robotics to develop minimally invasive medical devices. The company's Focal One® system is designed to treat early-stage prostate cancer, with potential for expansion into multiple indications.
The company will host a conference call today at 8:30 a.m. EDT to discuss the credit facility and other financial developments.
References:
[1] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
• Focal One net placement grows 140% YoY. • HIFU revenue increases 76.8% YoY. • 36 million Euro credit facility with EIB to accelerate HIFU growth. • 2025 HIFU revenue growth guidance raised to 26%-34%. • Company to host conference call today at 8:30 a.m. EDT.
EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, has secured a €36 million credit facility from the European Investment Bank (EIB) to support the expansion of its Focal One® Robotic HIFU technology for early-stage prostate cancer treatment and accelerate the development of new clinical indications. The credit facility, expected to close by the end of 2025, will provide low-interest funding accessible in tranches, enhancing EDAP's balance sheet and supporting its growth strategy.The announcement follows a strong financial performance, with Focal One net placement growing 140% year-over-year (YoY) and HIFU revenue increasing by 76.8% YoY. The company has also raised its 2025 HIFU revenue growth guidance to a range of 26% to 34%.
CEO Ryan Rhodes highlighted the strategic significance of the financing, stating, "The capital raised through this financing immediately enhances our balance sheet, offering a substantial source of low-interest funding that we can access in tranches as needed. Over the last several years, the EIB has been an extraordinary partner in helping companies deliver new and promising innovative technologies for the benefit of millions of patients across the globe. I would like to thank the EIB for their support, as we believe this additional capital will enable more physicians and their patients to access the benefits of Focal One Robotic HIFU."
EDAP TMS SA is recognized for its innovation in robotic energy-based therapies, combining ultrasound technology with advanced imaging and robotics to develop minimally invasive medical devices. The company's Focal One® system is designed to treat early-stage prostate cancer, with potential for expansion into multiple indications.
The company will host a conference call today at 8:30 a.m. EDT to discuss the credit facility and other financial developments.
References:
[1] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios